FdaApplication
NDA 213690
Identifiers
- fda_app_no: NDA213690
Properties
| Property | Value |
|---|---|
| applicant_name | JOURNEY MEDICAL CORP |
| application_type | NDA |
| approval_date | 2020-05-28 |
Revenue by product
ZILXI
| Period | Revenue |
|---|---|
| Q2 2026 | $0.9M |
| Q1 2026 | $1.1M |
| Q4 2025 | $1.9M |
| Q3 2025 | $1.3M |
| Q2 2025 | $1.4M |
| Q1 2025 | $2.0M |
| Q4 2024 | $2.4M |
| Q3 2024 | $2.7M |
| Q2 2024 | $0.4M |
| Q1 2024 | $0.3M |
| Q4 2023 | $0.4M |
| Q3 2023 | $0.7M |
| Q2 2023 | $0.6M |
| Q1 2023 | $0.3M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ZILXI | MINOCYCLINE HYDROCHLORIDE | EQ 1.5% BASE | AEROSOL, FOAM;TOPICAL |
1 product